Original language | English (US) |
---|---|
Pages (from-to) | 1300-1301 |
Number of pages | 2 |
Journal | JAMA Oncology |
Volume | 4 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2018 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In reply. / Prasad, Vinay; Kaestner, Victoria; Mailankody, Sham.
In: JAMA Oncology, Vol. 4, No. 9, 09.2018, p. 1300-1301.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - In reply
AU - Prasad, Vinay
AU - Kaestner, Victoria
AU - Mailankody, Sham
N1 - Funding Information: Conflict of Interest Disclosures: Dr Richardson has received honoraria for advisory boards from Genentech and AstraZeneca. Dr Coleman has grant support from Roche/Genentech, AstraZeneca, Clovis, AbbVie, Merck, and Janssen. No other disclosures are reported. 1. Richardson DL, Sill MW, Coleman RL, et al. Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial. JAMA Oncol. 2018;4(2):196-202. doi:10.1001/jamaoncol.2017.4218 2. Pignata S, Lorusso D, Scambia G, et al; MITO 11 investigators. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16(5):561-568. doi:10.1016/S1470-2045(15)70115-4 3. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. doi:10.1200/JCO.2013.51.4489 4. Osman MA, Elkady MS, Nasr KE. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin Med Insights Oncol. 2016;10:35-41. doi:10.4137/CMO.S38204 Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported.
PY - 2018/9
Y1 - 2018/9
UR - http://www.scopus.com/inward/record.url?scp=85053411864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053411864&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2018.1715
DO - 10.1001/jamaoncol.2018.1715
M3 - Letter
AN - SCOPUS:85053411864
VL - 4
SP - 1300
EP - 1301
JO - JAMA oncology
JF - JAMA oncology
SN - 2374-2437
IS - 9
ER -